No matter whether you’re an end user or an OEM in biophotonics, biomedical optics, and imaging, Coherent has the laser that perfectly matches your needs and your budget.
A new study on the persistence of neutralising antibodies to SARS-CoV-2 in the blood suggests that humoral immunity will drop 5 months after vaccination.
Francesco Maria Lavino has been appointed as Chief Executive Officer of F2G Ltd., a biopharmaceutical company, based in UK and Austria, and specialised in fungal infections.
Swiss BioVersys has received €20mfrom the European Investment Bank to push the development of new drugs against life-threatening nosocomial infections.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.